BioXell, Cosmo deal

Specialty pharmaceutical company Cosmo will acquire BioXell in a cash, stock and put option transaction that the companies said values BioXell at CHF7.68 per share, or CHF41.3 million

Read the full 282 word article

How to gain access

Continue reading with a
two-week free trial.